SeqOnce Biosciences Expands Pathogen Assay Suite
SeqOnce Biosciences, a leader in the development of advanced genomic tools, recently announced a significant enhancement to their pathogen assay offerings with the introduction of their new Measles Panel A. This innovative product has been designed specifically for professionals in the infectious disease research and CLIA testing market, and it reflects SeqOnce's dedication to improving public health through cutting-edge technology.
Commitment to Innovation and Customer Needs
CEO Chris Angermayer expressed that this latest expansion of their RT-qPCR assays demonstrates their commitment to collaboration and innovation in pathogen analysis. He emphasized, "This expansion ensures that we can effectively support our partners through various phases of their research, from development to clinical applications. Our goal is to enhance safety within communities by providing indispensable genomic tools that cater to their needs."
The Importance of Measles Panel A
Developed in response to a notable rise in measles cases, Measles Panel A is engineered to be compatible with the leading qPCR systems including Bio-Rad, Roche, and ABI. This assay has unique capabilities, such as detecting the D8 genotype associated with recent outbreaks, as well as all known circulating viruses. The introduction of this panel reflects SeqOnce's proactivity in addressing public health challenges head-on.
User-Centered Product Development
Dr. Joe Dunham, the Chief Science Officer, shared insights into their creative process, stating, "Our development is driven by direct engagement with our customers. Understanding the trends within the marketplace allows us to innovate effectively. We utilize powerful Bioinformatic tools to tailor our product panels, ensuring compatibility with our enzymes, fluorophores, and buffers, which together help us produce high-quality results."
Expanding Product Portfolio
SeqOnce’s existing product portfolio already includes multiplex qPCR assays aimed at various health sectors, including respiratory diseases, women's health, and antibiotic resistance. Their ongoing commitment to expand their offerings suggests that they will continue to listen to market needs and adapt accordingly.
About SeqOnce Biosciences
SeqOnce Biosciences, Inc. is a privately held company focused on developing genomic tools that address the complexities of infectious diseases. Even though their main office is situated in California, their impact is felt globally as they strive to innovate within the realm of qPCR and NGS technologies designed exclusively for research purposes.
Contact Information
For those interested in obtaining more information about SeqOnce Biosciences, you can reach Chris Angermayer directly at 1 (626) 460-3050. Their website remains a valuable resource for additional details regarding all their product offerings.
Frequently Asked Questions
What is the Measles Panel A designed to do?
The Measles Panel A is designed to detect both the D8 genotype of measles and all known circulating viruses.
Who is the CEO of SeqOnce Biosciences?
The current CEO of SeqOnce Biosciences is Chris Angermayer.
What kind of systems is the Measles Panel A compatible with?
The Measles Panel A is compatible with Bio-Rad, Roche, and ABI qPCR systems.
What areas does SeqOnce focus on?
SeqOnce focuses on infectious disease, qPCR, NGS, and developing novel technology platforms for research purposes.
How can I contact SeqOnce Biosciences for more information?
You can contact Chris Angermayer at 1 (626) 460-3050 for more information regarding SeqOnce Biosciences.
